MHRA approves elinzanetant to treat moderate to severe vasomotor symptoms (hot flushes) caused by menopause  

The Medicines and Healthcare products Regulatory Agency (MHRA) has today, 8 July, become the first regulator in the world to approve elinzanetant (Lynkuet) for the treatment of moderate to severe vasomotor symptoms (hot flus…

Follow this news feed: